Precision BioSciences (DTIL) Tops Q2 EPS by 40c; Reports Cash and Cash Equivalents of $160.5M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Precision BioSciences Reports Third Quarter 2021 Financial Results and Provides Business Update
November 10, 2021 7:00 AM EST- Appointed Michael Amoroso as President and Chief Executive Officer and to Board of Directors; Sam Wadsworth, Ph.D., and Shari Lisa Piré, J.D., Appointed to Board of Directors
- Hosted In Vivo Gene Editing R&D Event and Outlined Plans for Accelerated Path to Clinic for Three Investigational New Drug/Clinical Trial Applications Within Next Three Years
- Announced In Vivo Gene Editing License and Collaboration Agreement with iECURE to Advance Precision BioSciences Wholly-Owned PCSK9 Program for Familial Hypercholesterolemia Through Phase 1 and Develop Four ARCUS-Based Gene... More
